November 2005
Worldwide Biotech;Nov2005, Vol. 17 Issue 11, p6
Trade Publication
No abstract available.


Related Articles

  • INDIA AND CII SUPPORT AETHLON HIV/HEPATITIS TRIALS.  // Worldwide Biotech;May2005, Vol. 17 Issue 5, p5 

    Reports on the support of the Indian government and the Confederation of Indian Industry for the HIV and hepatitis C trials to be conducted by Aethlon Medical Inc. in India in 2005. Statement issued by Sandeep Malik of Qualtran, a contract research organization that will manage the clinical...

  • Data looks 'optimistic' for the first device to treat HIV.  // Medical Technology & Devices Week;2/2/2009, Vol. 7 Issue 5, p1 

    The article reports on the plan of Aethlon Medical to release first-in-human study findings on its Hemopurifier, the first extracorporeal device for treating HIV infection, in mid-February 2009. The device resembles the natural immune response of eliminating infectious viruses and toxins before...

  • Aethlon establishes HCV program with Medanta.  // Medical Device Daily;8/10/2012, Vol. 16 Issue 155, p2 

    The article reports on the plan of Aethlon Medical to establish an hepatitis C virus (HCV) treatment program at the Medanta Medicity Institute.

  • Update on the Treatment of Patients With Non–Genotype 1 Hepatitis C Virus Infection. Mangia, Alessandra; Mottola, Leonardo; Piazzolla, Valeria // Clinical Infectious Diseases;May2013, Vol. 56 Issue 9, p1294 

    We focus on the treatment of hepatitis C virus genotypes 2 and 3 with coverage of clinical trials on short-duration treatment course, use of weight-based ribavirin, impact of cirrhosis on treatment decisions, and retreatment of patients with previous treatment failure.Current treatment for...

  • Med-Tech Notes.  // Medical Device Daily;12/5/2012, Vol. 16 Issue 235, p4 

    This section presents updates on medical technology. Vascular Closure Systems concluded Phase I and Phase II of the First in Human (FIH) clinical trial for its 6 Fr./7 Fr. FastSeal bioabsorbable vascular access closure system. Aethlon Medical launched a compassionate-use clinical program for...

  • Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. Kobayashi, Masahiro; Ikeda, Kenji; Arase, Yasuji; Suzuki, Yoshiyuki; Suzuki, Fumitaka; Akuta, Norio; Hosaka, Tetsuya; Murashima, Naoya; Saitoh, Satoshi; Someya, Takashi; Tsubota, Akihito; Kumada, Hiromitsu // Journal of Gastroenterology;2008, Vol. 43 Issue 1, p63 

    Background. A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branchedchain amino acid (BCAA) granules for oral use (TK-98) on disease progression. Methods. Patients who had compensated liver cirrhosis due to...

  • Hepatitis C Viral Evolution in Genotype 1 Treatment-Na�ve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. Kieffer, Tara L.; De Meyer, Sandra; Bartels, Doug J.; Sullivan, James C.; Zhang, Eileen Z.; Tigges, Ann; Dierynck, Inge; Spanks, Joan; Dorrian, Jennifer; Min Jiang; Adiwijaya, Bambang; Ghys, Anne; Beumont, Maria; Kauffman, Robert S.; Adda, Nathalie; Jacobson, Ira M.; Sherman, Kenneth E.; Zeuzem, Stefan; Kwong, Ann D.; Picchio, Gaston // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic changes could be observed in TVR-treated...

  • Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Romero, Miriam; Pérez-Olmeda, Mayte; García-Samaniego, Javier; Soriano, Vicente; Pérez-Olmeda, Mayte; García-Samaniego, Javier // Drug Safety;2004, Vol. 27 Issue 1, p7 

    Hepatitis C virus (HCV) infection is a significant public health problem and one of the most important causes of chronic liver disease worldwide. Co-infection with HCV and HIV occurs frequently, mainly because both viruses share the same transmission routes. In recent years, the life expectancy...

  • GILEAD/ACHILLION INITIATE GS 9132 PHASE I CLINICAL TRIAL.  // Biotech Business;Nov2005, Vol. 18 Issue 11, p1 

    Reports that Gilead Sciences and Achillion Pharmaceuticals have initiated the phase I clinical trial of GS 9132 for the treatment of hepatitis C. Agreement between Gilead and Achillion regarding GS 9132 small molecule inhibitor of hepatitis C virus; Information on hepatitis C; Background of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics